GOLDMAN MYLA LAI
CIK 1168581 · EVP & Chief Medical Officer · last filed 2026-07-09
GOLDMAN MYLA LAI is an EVP & Chief Medical Officer who has filed 63 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for QTRX, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$6.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$16.08M
5
63
-$6.85M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTRX | Director | 15,041 | $3.49 | $52.5K | $0 | 4 | 2026-07-09 |
| WST | Director | 20,434 | $337.00 | $6.89M | $0 | 25 | 2026-05-06 |
| Akoya Biosciences, Inc. (AKYA) Delisted | Director | 20,000 | $1.29 | $25.8K | $100.0K | 5 | 2024-06-05 |
| SEQUENOM INC (SQNM) Delisted | Director | 0 | — | — | $18.4K | 10 | 2016-09-07 |
| LH | EVP & Chief Medical Officer | 29,090 | $314.23 | $9.14M | -$6.97M | 18 | 2008-11-24 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-09 | QTRX | Exer (M) | +8,073 | $0 | EDGAR |
| 2026-05-06 | WST | Grant (A) | +791 | $0 | EDGAR |
| 2026-01-06 | QTRX | Grant (A) | +25,316 | $0 | EDGAR |
| 2025-10-03 | QTRX | Grant (A) | +2,084 | $11.5K | EDGAR |
| 2025-07-10 | — | Other (J) | −20,000 | $0 | |
| 2025-07-10 | QTRX | Grant (A) | +27,404 | $0 | EDGAR |
| 2025-05-08 | WST | Grant (A) | +1,071 | $0 | EDGAR |
| 2024-06-05 | Akoya Biosciences, Inc. (AKYA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-25 | WST | Grant (A) | +564 | $0 | EDGAR |
| 2023-06-12 | Akoya Biosciences, Inc. (AKYA) Delisted | Buy (P) | +20,000 | $100.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.